JUPITER NEUROSCIENCES INC (JUNS) Stock Price & Overview
NASDAQ:JUNS • US48208B2034
Current stock price
The current stock price of JUNS is 0.341 USD. Today JUNS is down by -7.51%. In the past month the price decreased by -11.89%. In the past year, price decreased by -35.83%.
JUNS Key Statistics
- Market Cap
- 11.741M
- P/E
- N/A
- Fwd P/E
- 5.57
- EPS (TTM)
- -0.26
- Dividend Yield
- N/A
JUNS Stock Performance
JUNS Stock Chart
JUNS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to JUNS. When comparing the yearly performance of all stocks, JUNS is a bad performer in the overall market: 95.21% of all stocks are doing better.
JUNS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to JUNS. Both the profitability and financial health of JUNS have multiple concerns.
JUNS Earnings
On April 1, 2026 JUNS reported an EPS of -0.07 and a revenue of 22.00K. The company beat EPS expectations (6.16% surprise) and missed revenue expectations (-71.24% surprise).
JUNS Forecast & Estimates
7 analysts have analysed JUNS and the average price target is 25.5 USD. This implies a price increase of 7378.01% is expected in the next year compared to the current price of 0.341.
For the next year, analysts expect an EPS growth of 123.81% and a revenue growth 16076.5% for JUNS
JUNS Groups
Sector & Classification
JUNS Financial Highlights
Over the last trailing twelve months JUNS reported a non-GAAP Earnings per Share(EPS) of -0.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -294.9% | ||
| ROE | -13236.06% | ||
| Debt/Equity | 2.55 |
JUNS Ownership
JUNS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.52 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.69 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.838B | ||
| PFE | PFIZER INC | 9.32 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.37 | 121.374B | ||
| ZTS | ZOETIS INC | 16.71 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.16 | 28.018B | ||
| VTRS | VIATRIS INC | 5.35 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.69 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.44 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JUNS
Company Profile
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Company Info
IPO: 2024-12-03
JUPITER NEUROSCIENCES INC
1001 North US HWY 1, Suite 504
Palm Beach Gardens FLORIDA US
Employees: 4
Phone: 15614066154
JUPITER NEUROSCIENCES INC / JUNS FAQ
What does JUPITER NEUROSCIENCES INC do?
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Can you provide the latest stock price for JUPITER NEUROSCIENCES INC?
The current stock price of JUNS is 0.341 USD. The price decreased by -7.51% in the last trading session.
What is the dividend status of JUPITER NEUROSCIENCES INC?
JUNS does not pay a dividend.
What is the ChartMill technical and fundamental rating of JUNS stock?
JUNS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting JUNS stock to perform?
7 analysts have analysed JUNS and the average price target is 25.5 USD. This implies a price increase of 7378.01% is expected in the next year compared to the current price of 0.341.
Can you provide the PE ratio for JUNS stock?
JUPITER NEUROSCIENCES INC (JUNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
Can you provide the market cap for JUPITER NEUROSCIENCES INC?
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalization of 11.74M USD. This makes JUNS a Nano Cap stock.